Format

Send to

Choose Destination
Expert Rev Vaccines. 2008 Sep;7(7):963-75. doi: 10.1586/14760584.7.7.963.

Strategies used for MUC1 immunotherapy: human clinical studies.

Author information

1
Burnet Institute, Austin Campus, Immunology and Vaccine Laboratory, Studley Road, Heidelberg, VIC 3084, Australia. cktang@burnet.edu.au

Abstract

MUC1 is a high-molecular-weight glycoprotein that is overexpressed in adenocarcinomas and hematological cancers. Numerous preclinical studies in mice have demonstrated that MUC1 is immunogenic, and that cellular and humoral immune responses could be induced depending on the MUC1 vaccine formulation. MUC1-based vaccines have quickly entered into human clinical trials, and immune responses and some clinical responses have been reported. Here, we give an up-to-date review of some of the MUC1-based vaccines that have entered clinical trials and their results in cancer patients.

PMID:
18767946
DOI:
10.1586/14760584.7.7.963
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center